Glycaemic Effects of Non-statin Lipid-Lowering Therapies

Current Cardiology Reports

Volumn 18, Issue 12, 2016, Pages

  Collins, Patrick D ^a   Sattar, Naveed ^b  

^a UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Diabetes; Ezetimibe; Hypercholesterolaemia; Niacin; PCSK9; Statins

Indexed keywords

ALIROCUMAB; BOCOCIZUMAB; EVOLOCUMAB; EZETIMIBE; FIBRIC ACID DERIVATIVE; NICOTINIC ACID; ANTILIPEMIC AGENT; GLUCOSE BLOOD LEVEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

CLINICAL DECISION MAKING; DISEASE EXACERBATION; DRUG EFFECT; DRUG POTENCY; DRUG RESEARCH; FOLLOW UP; GENETIC VARIATION; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; METABOLIC SYNDROME X; PROTEIN DEGRADATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; LIPID METABOLISM; META ANALYSIS (TOPIC); METABOLISM; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EZETIMIBE; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; META-ANALYSIS AS TOPIC; NIACIN; PROPROTEIN CONVERTASE 9; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84995893132     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-016-0795-9     Document Type: Review

References (31)

1. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEJM. 2008;359:2195–207.
2. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.
3. •Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385:351–61. This paper demonstrates the power to link genetics and clinical trial data to improve causal understanding of the effects of drug therapy on adverse effects; in this case, examining the diabetogenic effects of statins.
4. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–64.
5. Ostrowska M, Adamski P, Kosinski M, et al. Diabetogenic effect of statins: a comprehensive review on the clinical relevance, underlying pathomechanisms and rationale for tailored statin therapy. Folia Med Copernicana. 2015;3:145–53.
6. Ford I, Murray H, Packard C, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. NEJM. 2007;357:1477–86.
7. Shepherd J, Blauw GJ, Murphy MB, PROSPER Study Group, et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.
8. Besseling J, Kastelein JJP, Defesche JC, et al. Association between familial hypercholesterolaemia and prevalence of type 2 diabetes mellitus. JAMA. 2015;313:1029–36.
9. •Fall T, Xie W, Poon W, et al. Using Genetic variants to assess the relationship between circulating lipids and type 2 diabetes. Diabetes. 2015;64:2676–84. Demonstrates the power of genetics to improve understanding of complex biological links, but also the potential caveats one must consider.
10. Coulhoun HM, Ginsberg HN, Robinson JG et al.: No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies. European Heart Journal. 2016; ehw292 [Epub ahead of print]. The first study to examine whether there is any obvious and immediate effect of PCSK9 inhibition (alirocumab in this case) on diabetes risk and glycaemia levels.
11. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidaemia. NEJM. 2014;370:1809–19.
12. Henry RR, Holman RR, Giugliano RP, et al. Effects of long-term, monthly administration of the PCSK9 inhibitor evolocumab in patients with dysglycemia or metabolic syndrome. Can J Diabetes. 2014;38:S18.
13. Sattar N, Preiss D, Robinson JG, et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016;4:403–10.
14. ••Lotta LA, Sharp SJ, Burgess S, et al. Association Between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: A meta-analysis. JAMA. 2016;4;316(13):1383-1391. This is the first large genetic study of PCSK9 snps and diabetes risk and shows a significant higher risk, albeit modestly so, but with stronger associations with diabetes for genes encoding the molecular targets for ezetimibe.
15. •Sattar N. PCSK9 inhibitors and diabetes risk: a question worth asking? Eur Heart J. 2016. doi:10.1093/eurheartj/ehw346. This commentary pulls together the existing evidence for statins and PCSK9 and risks of diabetes and gives clinical implications as well as important areas for future research.
16. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–55.
17. HPS2-THRIVE collaborative group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. NEJM. 2014;371:203–12.
18. AIM-HIGH investivators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. NEJM. 2011;365:2255–67.
19. Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc. 2008;83:470–80.
20. Sazonov V, Maccubbin D, Sisk CM, et al. Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. Int J Clin Pract. 2013;67:297–302.
21. •Goldie C, Taylor AJ, Nguyen P, et al. Niacin therapy and the risk of new-onset diabetes: a meta-aaalysis of randomised controlled trials. Heart. 2016;102:198–203. A well-conducted meta-analysis of trials of Niacin and its risk for diabetes.
22. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223:251–61.
23. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. NEJM. 2015;372:2387–97.
24. Saito I, Azuma K, Kakikawa T, et al. A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolaemia. Lipids Health Dis. 2015;14:40.
25. •Blazing MA, on behalf of the IMPROVE-IT Investigators. Incidence of new onset diabetes in the IMPROVE-IT trial: does adding ezetimibe to simvastatin increase risk compared to simvastatin alone? London: Presented at: European Society of Cardiology Congress; 2015. An early examination of the risks of diabetes with ezetimibe.
26. Jun M, Foote C, Licheng LV, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875–84.
27. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61.
28. Lee CY, Huang KH, Lin CC, et al. A neutral risk on the development of new-onset diabetes mellitus (NODM) in Taiwanese patients with dyslipidaemia treated with fibrates. Scientific World Journal. 2012;2012:392734.
29. Tenenbaum A, Motro M, Fisman EZ, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004;109:2197–202.
30. Silbernagel G, Stefan N, Hoffmann MM, et al. The L162V polymorphism of the peroxysome proliferator activated receptor alpha gene (PPARA) is not asocialted with type 2 diabetes, BMI or body fat composition. Exp Clin Endocrine Diabetes. 2009;117:113–8.
31. Baker WL, Talati R, White CM, et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87:98–107.